Effect of Thiopurine on Potential Surgical Intervention in Crohn’s Disease in Korea: Results from the CONNECT Study

• Main Authors: Hee Man Kim, Jin Woo Kim, Hyun-Soo Kim, Joo Sung Kim, You Sun Kim, Jae Hee Cheon, Won Ho Kim, Byong Duk Ye, Won Moon, Sung Hee Jung, Young-Ho Kim, Dong Soo Han
• Format: Article
• Language: English
• Published: MDPI AG 2021-12-01
• Series: Journal of Clinical Medicine
• Subjects: Crohn’s disease; surgery; Azathioprine; TNF-α antagonist
• Online Access: https://www.mdpi.com/2077-0383/10/1/25

<b>Objectives:</b> The incidence of Crohn’s disease and the number of associated surgeries are increasing in Korea. This study investigated the effect of azathioprine/6-mercaptopurine (6-MP) and TNF-α antagonists on abdominal and perianal surgery in Korean patients with Crohn’s disease. <b>Design:</b> A retrospective cohort study<b>. </b><b>Setting:</b> Data from the Crohn’s Disease Clinical Network and Cohort (CONNECT) were used. Patients with confirmed Crohn’s disease between 1982 and 2008 from 32 hospitals in the Republic of Korea were enrolled. The effect of azathioprine/6-MP on abdominal and perianal surgery was analysed using logistic regression analysis adjusting for age and sex. <b>Participants</b><b>:</b> In total, 1161 Crohn’s disease patients were included in the Republic of Korea in the surgery (<i>n</i> = 462, male = 339, female = 123) and control groups (<i>n</i> = 699, male = 484, female = 215). <b>Results:</b> In total, 1161 patients were selected, with 462 patients who underwent abdominal (<i>n</i> = 245) or perianal surgery (<i>n</i> = 217). The preoperative usage rates of azathioprine/6-MP were 18.8% and 65.1% (<i>p</i> < 0.0001) in the surgery and control groups, respectively. The preoperative usage rates of TNF-α antagonists were 7.1% and 23.3% (<i>p</i> < 0.0001) in the surgery and control groups, respectively. A multivariate analysis revealed that the preoperative use of azathioprine/6-MP had an odds ratio of 0.094 for all surgeries (95% confidence interval [CI]: 0.070–0.127, <i>p</i><i> </i><<i> </i>0.0001), 0.131 for abdominal surgery (95% CI: 397–1.599, <i>p</i><i> </i><<i> </i>0.0001), and 0.059 for perianal surgery (95% CI: 0.038–0.091, <i>p</i><i> </i><<i> </i>0.0001). The preoperative use of TNF-α antagonists had an odds ratio of 0.225 for all surgeries (95% CI: 0.151–0.335, <i>p</i><i> </i><<i> </i>0.0001), 0.403 for abdominal surgery (95% CI: 0.261–0.623, <i>p</i><i> </i><<i> </i>0.0001), and 0.064 for perianal surgery (95% CI: 0.026–0.160, <i>p</i><i> < </i>0.001). <b>Strengths of this study:</b> The study presents new evidence of the reduced risk of surgery following azathioprine use in Crohn’s disease patients. <b>Limitations of this study</b> (1) This was not a controlled prospective study. (2) There was a selection bias specific to the CONNECT cohort. (3) The combination or sequential use of azathioprine/6-MP and TNF-α antagonists was not excluded. <b>Conclusion:</b> Azathioprine/6-MP is significantly associated with a reduced risk of abdominal and perianal surgery in Korean patients with Crohn’s disease.